Kala Bio (KALA) Assets Average (2017 - 2026)
Kala Bio's (KALA) quarterly Assets Average came in at $11.4 million in Q2 2026, down 72.84% year-over-year from $42.2 million in Q2 2025, and up 5.01% quarter-over-quarter from $10.9 million in Q1 2026.
Analysis
Kala Bio (KALA) Assets Average (2017 - 2026) Analysis & Trends
Kala Bio has disclosed Assets Average across 10 years of filings, most recently posting $11.4 million for Q2 2026.
- In Q2 2026, Assets Average fell 72.84% year-over-year to $11.4 million; the TTM figure through Jun 2026 stood at $11.4 million (down 72.84% YoY), while the FY2025 annual figure was $32.5 million, down 41.69% from the prior year.
- Assets Average came in at $11.4 million for Q2 2026 at Kala Bio, up from $10.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $125.5 million in Q1 2022 to a low of $10.9 million in Q1 2026.
- Average Assets Average over 5 years is $58.6 million, with a median of $57.6 million recorded in 2024.
- Year-over-year, Assets Average decreased 4.81% in 2025 and tumbled 78.98% in 2026.
- Over 5 years, Assets Average stood at $86.3 million in 2022, then tumbled by 32.14% to $58.5 million in 2023, then dropped by 6.41% to $54.8 million in 2024, then sank by 68.5% to $17.3 million in 2025, then slumped by 33.64% to $11.4 million in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $11.4 million in Q2 2026, $10.9 million in Q1 2026, and $17.3 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.55 Bn | 192.56 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 180.15 Bn | 176.98 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 131.59 Bn | 123.73 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 81.98 Bn | 73.98 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 60.33 Bn | 55.14 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.75 Bn | 48.61 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 33.06 Bn | 29.76 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.95 Bn | 30.67 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 29.25 Bn | 29.25 Bn | 1.16 Mn | 5.51 Bn |
| 10 | Kala Bio | 8.44 Mn | 8.44 Mn | - | 11.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.45 Mn |
| Mar 31, 2026 | 10.90 Mn |
| Dec 31, 2025 | 17.26 Mn |
| Sep 30, 2025 | 30.54 Mn |
| Jun 30, 2025 | 42.15 Mn |
| Mar 31, 2025 | 51.87 Mn |
| Dec 31, 2024 | 54.78 Mn |
| Sep 30, 2024 | 57.84 Mn |
| Jun 30, 2024 | 57.32 Mn |
| Mar 31, 2024 | 54.49 Mn |
| Dec 31, 2023 | 58.53 Mn |
| Sep 30, 2023 | 63.81 Mn |
| Jun 30, 2023 | 69.36 Mn |
| Mar 31, 2023 | 79.52 Mn |
| Dec 31, 2022 | 86.26 Mn |
| Sep 30, 2022 | 85.34 Mn |
| Jun 30, 2022 | 98.28 Mn |
| Mar 31, 2022 | 125.50 Mn |
| Dec 31, 2021 | 166.62 Mn |
| Sep 30, 2021 | 204.64 Mn |